BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 12571219)

  • 1. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
    Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
    J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients.
    Koral KF; Kaminski MS; Wahl RL
    J Nucl Med; 2003 Sep; 44(9):1541-3; author reply 1543. PubMed ID: 12960205
    [No Abstract]   [Full Text] [Related]  

  • 3. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
    Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
    Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
    J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
    Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
    J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
    Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
    Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.
    Ferrer L; Malek E; Bodet-Milin C; Legouill S; Prangère T; Robu D; Jeans S; Tipping J; Huglo D; Carpentier P; Illidge T; Kraeber-Boderé F; Morschhauser F; Bardiès M
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):529-37. PubMed ID: 23358406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
    Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
    J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.
    Amro H; Wilderman SJ; Dewaraja YK; Roberson PL
    J Nucl Med; 2010 Apr; 51(4):654-9. PubMed ID: 20237032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
    Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
    Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
    J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
    Dewaraja YK; Schipper MJ; Roberson PL; Wilderman SJ; Amro H; Regan DD; Koral KF; Kaminski MS; Avram AM
    J Nucl Med; 2010 Jul; 51(7):1155-62. PubMed ID: 20554734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
    Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
    Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
    J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma.
    Boucek JA; Turner JH
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):458-69. PubMed ID: 15821965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
    Blakkisrud J; Løndalen A; Martinsen AC; Dahle J; Holtedahl JE; Bach-Gansmo T; Holte H; Kolstad A; Stokke C
    J Nucl Med; 2017 Jan; 58(1):48-54. PubMed ID: 27493270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.